International Society for the Study of Women's Sexual Health

NEWS

General Statement of the International Society for the Study of Women's Sexual Health

The International Society for the Study of Women's Sexual Health (ISSWSH), the preeminent scientific organization focused on research, education, and clinical practice of women's sexuality, applauds the FDA's recent announcement of it's upcoming Joint Meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee on June 4, 2015.

The meeting culminates the prolonged development of flibanserin, a drug that could be the first approved medical treatment for distressing low sexual desire. Flibanserin offers a favorable safety and efficacy profile for the treatment of Hypoactive Sexual Desire Disorder in women. While we fully endorse the FDA's evidence-based review of the risks and benefits of this treatment, ISSWSH wishes to emphasize the significant unmet need for safe and effective medical therapies to address all women's sexual problems.

Save the Date


ISSWSH Annual Meeting 2017

  February 23-26, 2017  1 days left
  Grand Hyatt Atlanta, Atlanta, GA - USA
Read more...


ISSWSH Fall Course 2017

  November 2-5, 2017  253 days left
  DoubleTree Hilton Hotel, Scottsdale, AZ - USA
Read more...

Latest Tweets

Partners of men w/prostate cancer may report even more distress about diagnosis than patient himself https://t.co/M4jQugBqJr ISSWSH
Stephen Porges will reveal how female sexual function emerges from nuanced nervous system changes with stress & ill… https://t.co/YIcyXMmh3t ISSWSH
The Program for the ISSWSH 2017 Annual Meeting is available! https://t.co/lFkSxJg2La https://t.co/YQepamiiYq ISSWSH

Contact Details

ISSWSH Executive Office
PO Box 1233
Lakeville, MN 55044
USA

Phone: +1 (952) 683 9025
Fax: +1 (612) 808 0491
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.